ALNYAlnylam Pharmaceuticals, Inc.

Filing: 10-Q | Filed with the SEC on: October 29, 2026 | Period: Q3 FY2026 Current Price: $191.60 | Today's Change: -17.56%

---

What Happened

Alnylam Pharmaceuticals filed its quarterly report (10-Q) with the SEC on October 29, 2026, disclosing results for the third quarter of fiscal year 2026. The filing reveals net revenues of $2.617 billion for the Q3 2026 period, a figure that reflects substantial scale in the company's commercial operations relative to its full-year FY2022 revenue of $492.9 million — underscoring the dramatic transformation of ALNY's revenue base over recent years. Operating income came in at $369.9 million, a meaningful milestone for a company that has historically operated at a loss, while basic earnings per share reached $1.55 and diluted EPS landed at $1.51.

Despite the headline operating profit, the company reported a net loss of $18.3 million for the Q3 2026 period, indicating that below-the-line items — such as interest expense, tax provisions, or other non-operating charges — offset the operating-level profitability.

---

Why It Matters

The juxtaposition of a $369.9 million operating profit against a $18.3 million net loss is the critical tension in this filing. Investors will need to scrutinize the non-operating items responsible for the gap — whether that's debt servicing costs, tax-related adjustments, or other charges — as these will shape the path to sustained net profitability. The sharp single-day stock decline of over 17% suggests the market's reaction extends beyond the headline numbers, potentially reflecting guidance, pipeline updates, or other disclosures within the 10-Q that are not captured in the structured XBRL data provided here.

Key points for investors to consider:

• Revenue scale is real: $2.617 billion in a single quarter is a landmark figure versus the company's FY2022 full-year base of $492.9 million, confirming the commercial maturity of ALNY's RNAi franchise.
• Operating profitability is confirmed: An operating income of nearly $370 million signals that the core commercial business is generating cash at the operating level.
• Net loss persists: The $18.3 million net loss, despite strong operating performance, points to meaningful below-the-line headwinds that investors should monitor closely.
• Stock reaction is severe: The -17.56% intraday move is well outside normal volatility and strongly implies that something within the full 10-Q filing — beyond what is captured in the XBRL facts — is driving significant investor concern.

---

Analysis

This filing presents a bifurcated picture. On one hand, Alnylam's commercial engine is clearly firing — quarterly revenues approaching $2.62 billion and nearly $370 million in operating income represent a company that has successfully crossed into commercial-stage maturity. The contrast with FY2022's full-year revenue of just under $493 million makes the magnitude of that transformation strikingly apparent.

On the other hand, the persistence of a net loss even at this revenue scale, combined with the severity of today's stock selloff, warrants close attention to the full narrative of the 10-Q. The XBRL-derived figures confirm operational momentum, but the market's reaction suggests that either forward guidance, pipeline news, collaboration revenue dynamics, or expense trends disclosed elsewhere in the filing have raised questions about the durability or quality of that momentum.

This follows StockWatch's existing initiating coverage on ALNY — the pronounced market reaction today represents a materially changed trading context versus our coverage date. Readers should consult the full 10-Q filing directly to assess the non-operating items driving the net loss and any forward-looking disclosures that may be informing today's selloff.

What to watch next:

• The specific non-operating charges that converted a ~$370M operating profit into an $18M net loss
• Any changes to full-year 2026 revenue or operating guidance disclosed in the MD&A section
• Pipeline or regulatory updates included in the filing that may be impacting sentiment
• Collaboration and royalty revenue breakdown within the $2.617B total

---

Disclaimer

This report is a news and informational summary of a public SEC filing. It does not constitute investment advice, and no buy, hold, or sell recommendation is made herein. The financial figures cited are drawn exclusively from the structured XBRL data extracted from Alnylam Pharmaceuticals' officially filed 10-Q. Readers should review the full SEC filing and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on ALNY, published 2026-10-01. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-29. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/alny-20260930.htm